{"id": "article-31270_0", "title": "Von Willebrand Disease -- Continuing Education Activity", "content": "Von Willebrand disease is a bleeding disorder caused by the qualitative or quantitative deficiency of the pro-von Willebrand factor. Affected people may complain of excessive bruising, prolonged bleeding from mucosal surfaces, and prolonged bleeding after minor trauma. This activity describes the evaluation and management of Von Willebrand disease and explains the role of the interprofessional team in improving care for patients with this condition.", "contents": "Von Willebrand Disease -- Continuing Education Activity. Von Willebrand disease is a bleeding disorder caused by the qualitative or quantitative deficiency of the pro-von Willebrand factor. Affected people may complain of excessive bruising, prolonged bleeding from mucosal surfaces, and prolonged bleeding after minor trauma. This activity describes the evaluation and management of Von Willebrand disease and explains the role of the interprofessional team in improving care for patients with this condition."}
{"id": "article-31270_1", "title": "Von Willebrand Disease -- Continuing Education Activity", "content": "Objectives: Identify the three types of inherited phenotypic forms of Von Willebrand disease. Summarize the pathophysiology of Von Willebrand disease. Review the laboratory tests and coagulation profile used in the evaluation of Von Willebrand disease. Explain the importance of collaboration and communication among the interprofessional team members to counsel the patients on avoiding high-risk contact sports and when to seek medical help, which will enhance care coordination for those affected by Von Willebrand disease. Access free multiple choice questions on this topic.", "contents": "Von Willebrand Disease -- Continuing Education Activity. Objectives: Identify the three types of inherited phenotypic forms of Von Willebrand disease. Summarize the pathophysiology of Von Willebrand disease. Review the laboratory tests and coagulation profile used in the evaluation of Von Willebrand disease. Explain the importance of collaboration and communication among the interprofessional team members to counsel the patients on avoiding high-risk contact sports and when to seek medical help, which will enhance care coordination for those affected by Von Willebrand disease. Access free multiple choice questions on this topic."}
{"id": "article-31270_2", "title": "Von Willebrand Disease -- Introduction", "content": "Von Willebrand factor is a glycoprotein that plays a part in hemostasis. It is synthesized in endothelial cells and megakaryocytes. After transcription and translation, pro-vWF is covalently linked to form dimers in the endoplasmic reticulum, and subsequently, large dimers form in the Golgi complex and secretory granules. The pro-von Willebrand factor\u00a0propeptide then undergoes cleavage, and then both the propeptide and mature\u00a0von\u00a0Willebrand factor\u00a0are secreted into the vessel lumen. It functions as a carrier for factor VIII to maintain its levels and help in platelet adhesion and binding to endothelial components after a vascular injury. Any qualitative or quantitative deficiency of pro-von\u00a0Willebrand factor will lead to an increased bleeding tendency, and this syndrome is called Von Willebrand disease. [1] [2] [3]", "contents": "Von Willebrand Disease -- Introduction. Von Willebrand factor is a glycoprotein that plays a part in hemostasis. It is synthesized in endothelial cells and megakaryocytes. After transcription and translation, pro-vWF is covalently linked to form dimers in the endoplasmic reticulum, and subsequently, large dimers form in the Golgi complex and secretory granules. The pro-von Willebrand factor\u00a0propeptide then undergoes cleavage, and then both the propeptide and mature\u00a0von\u00a0Willebrand factor\u00a0are secreted into the vessel lumen. It functions as a carrier for factor VIII to maintain its levels and help in platelet adhesion and binding to endothelial components after a vascular injury. Any qualitative or quantitative deficiency of pro-von\u00a0Willebrand factor will lead to an increased bleeding tendency, and this syndrome is called Von Willebrand disease. [1] [2] [3]"}
{"id": "article-31270_3", "title": "Von Willebrand Disease -- Etiology", "content": "Von Willebrand disease (VWD) can be inherited or acquired. [4] [5] Inherited phenotypic forms of\u00a0Von Willebrand disease\u00a0are: Type 1: This is an autosomal dominant disease (AD, incomplete penetrance approximately 60%) and is caused by a partial quantitative deficiency of von Willebrand\u00a0factor. Type 2: This is an autosomal dominant disease caused by several qualitative defects in\u00a0von\u00a0Willebrand factor. It has four subtypes (2A-AD or AR, 2B-AD, 2N-AR, 2M-AD). 2A is the most common variant. Type 3: This is an autosomal recessive disease (AR) and is caused by a complete quantitative defect. The von Willebrand\u00a0factor levels are not detectable, and the severe bleeding disorder characterizes this variant.", "contents": "Von Willebrand Disease -- Etiology. Von Willebrand disease (VWD) can be inherited or acquired. [4] [5] Inherited phenotypic forms of\u00a0Von Willebrand disease\u00a0are: Type 1: This is an autosomal dominant disease (AD, incomplete penetrance approximately 60%) and is caused by a partial quantitative deficiency of von Willebrand\u00a0factor. Type 2: This is an autosomal dominant disease caused by several qualitative defects in\u00a0von\u00a0Willebrand factor. It has four subtypes (2A-AD or AR, 2B-AD, 2N-AR, 2M-AD). 2A is the most common variant. Type 3: This is an autosomal recessive disease (AR) and is caused by a complete quantitative defect. The von Willebrand\u00a0factor levels are not detectable, and the severe bleeding disorder characterizes this variant."}
{"id": "article-31270_4", "title": "Von Willebrand Disease -- Etiology", "content": "The VWF gene is highly polymorphic, and this polymorphism leads to a big variation in the normal spectrum of von Willebrand\u00a0levels function. Subsequently, there is a spectrum of presentations and disease severity.", "contents": "Von Willebrand Disease -- Etiology. The VWF gene is highly polymorphic, and this polymorphism leads to a big variation in the normal spectrum of von Willebrand\u00a0levels function. Subsequently, there is a spectrum of presentations and disease severity."}
{"id": "article-31270_5", "title": "Von Willebrand Disease -- Etiology", "content": "Acquired von Willebrand disease\u00a0occurs when secondary (acquired) processes lead to a functional impairment of von Willebrand factor, either by decreasing its available quantity or interfering with the physiological hemostasis pathway. The most commonly associated conditions are lung cancer, Wilm's tumor, gastric cancer, MGUS, multiple myeloma, chronic lymphocytic leukemia, hairy cell leukemia, myeloproliferative neoplasms (MPN), plasma cell dyscrasias, lymphomas, systemic lupus\u00a0erythematosus (SLE), Felty syndrome, autoimmune hemolytic anemia, or other autoimmune disorders, metabolic disorders (hypothyroidism), drug side effects, and states of high-vascular flow such as AS, VSD, VAD (ventricular assist devices), extracorporeal membrane oxygenation (ECMO), or metallic cardiac valves. The\u00a0von Willebrand factor\u00a0is a large multimeric glycoprotein, and it is susceptible to the shear stress associated with high flow states.", "contents": "Von Willebrand Disease -- Etiology. Acquired von Willebrand disease\u00a0occurs when secondary (acquired) processes lead to a functional impairment of von Willebrand factor, either by decreasing its available quantity or interfering with the physiological hemostasis pathway. The most commonly associated conditions are lung cancer, Wilm's tumor, gastric cancer, MGUS, multiple myeloma, chronic lymphocytic leukemia, hairy cell leukemia, myeloproliferative neoplasms (MPN), plasma cell dyscrasias, lymphomas, systemic lupus\u00a0erythematosus (SLE), Felty syndrome, autoimmune hemolytic anemia, or other autoimmune disorders, metabolic disorders (hypothyroidism), drug side effects, and states of high-vascular flow such as AS, VSD, VAD (ventricular assist devices), extracorporeal membrane oxygenation (ECMO), or metallic cardiac valves. The\u00a0von Willebrand factor\u00a0is a large multimeric glycoprotein, and it is susceptible to the shear stress associated with high flow states."}
{"id": "article-31270_6", "title": "Von Willebrand Disease -- Etiology", "content": "The autoimmune spectrum can be quite varied as von Willebrand factor\u00a0occurs as a multimer, and this heterogeneity means that certain multimer sizes may escape the immune-mediated antibody response. The mechanism in malignancy includes the formation of non-specific antibodies that bind the\u00a0von Willebrand factor\u00a0forming an immune complex and hence increase clearance by the reticular endothelial system. The other mechanism is the absorption of the\u00a0von Willebrand factor\u00a0on the surface of malignant cells, such as the case in multiple myeloma or solid tumors or proteolysis of\u00a0von Willebrand factor\u00a0multimers as is usually seen in MPN.", "contents": "Von Willebrand Disease -- Etiology. The autoimmune spectrum can be quite varied as von Willebrand factor\u00a0occurs as a multimer, and this heterogeneity means that certain multimer sizes may escape the immune-mediated antibody response. The mechanism in malignancy includes the formation of non-specific antibodies that bind the\u00a0von Willebrand factor\u00a0forming an immune complex and hence increase clearance by the reticular endothelial system. The other mechanism is the absorption of the\u00a0von Willebrand factor\u00a0on the surface of malignant cells, such as the case in multiple myeloma or solid tumors or proteolysis of\u00a0von Willebrand factor\u00a0multimers as is usually seen in MPN."}
{"id": "article-31270_7", "title": "Von Willebrand Disease -- Epidemiology", "content": "Von Willebrand disease\u00a0is estimated to affect approximately 1% of the unselected population, but clinically significant disease prevalence is estimated to be about 125 per million, with severe disease affecting up to five per million.", "contents": "Von Willebrand Disease -- Epidemiology. Von Willebrand disease\u00a0is estimated to affect approximately 1% of the unselected population, but clinically significant disease prevalence is estimated to be about 125 per million, with severe disease affecting up to five per million."}
{"id": "article-31270_8", "title": "Von Willebrand Disease -- Epidemiology", "content": "There is an equal distribution between males and females. Acquired von Willebrand disease\u00a0prevalence is unknown but may represent 1% to 5% of all von Willebrand disease. Its prevalence is higher in certain groups. For example, it has been reported in up to 20% of malignancies and up to 100% of certain high flow states such as extracorporeal membrane oxygenation (ECMO) and metallic cardiac valves. [6]", "contents": "Von Willebrand Disease -- Epidemiology. There is an equal distribution between males and females. Acquired von Willebrand disease\u00a0prevalence is unknown but may represent 1% to 5% of all von Willebrand disease. Its prevalence is higher in certain groups. For example, it has been reported in up to 20% of malignancies and up to 100% of certain high flow states such as extracorporeal membrane oxygenation (ECMO) and metallic cardiac valves. [6]"}
{"id": "article-31270_9", "title": "Von Willebrand Disease -- Pathophysiology", "content": "Von Willebrand factor is a multimer formed from a basic dimer subunit. It is produced in megakaryocytes and endothelial cells. The size of the multimer determines the physiological hemostatic effect. Bigger multimers are more active and even prothrombic. They are cleaved by circulating proteases into smaller units. These larger multimers are stored in cytoplasmic granules and released in response to a trigger such as thrombin, fibrin, and histamine.", "contents": "Von Willebrand Disease -- Pathophysiology. Von Willebrand factor is a multimer formed from a basic dimer subunit. It is produced in megakaryocytes and endothelial cells. The size of the multimer determines the physiological hemostatic effect. Bigger multimers are more active and even prothrombic. They are cleaved by circulating proteases into smaller units. These larger multimers are stored in cytoplasmic granules and released in response to a trigger such as thrombin, fibrin, and histamine."}
{"id": "article-31270_10", "title": "Von Willebrand Disease -- Pathophysiology", "content": "Larger multimers have more available sites for binding to platelets and endothelium. Von Willebrand factor increases factor VIII half-life by preventing its degradation. Regarding the subtypes, type I is characterized by a mild decrease in\u00a0von Willebrand factor antigen (Ag),\u00a0von Willebrand factor\u00a0activity, and VIII:C.", "contents": "Von Willebrand Disease -- Pathophysiology. Larger multimers have more available sites for binding to platelets and endothelium. Von Willebrand factor increases factor VIII half-life by preventing its degradation. Regarding the subtypes, type I is characterized by a mild decrease in\u00a0von Willebrand factor antigen (Ag),\u00a0von Willebrand factor\u00a0activity, and VIII:C."}
{"id": "article-31270_11", "title": "Von Willebrand Disease -- Pathophysiology", "content": "Of note,\u00a0von Willebrand factor\u00a0levels of less than 30% are required for a diagnosis of Von Willebrand disease. Conversely, type III \u00a0is characterized by a significant decrease in the parameters above.", "contents": "Von Willebrand Disease -- Pathophysiology. Of note,\u00a0von Willebrand factor\u00a0levels of less than 30% are required for a diagnosis of Von Willebrand disease. Conversely, type III \u00a0is characterized by a significant decrease in the parameters above."}
{"id": "article-31270_12", "title": "Von Willebrand Disease -- Pathophysiology", "content": "A qualitative decrease with specific variations characterizes type II disease: Type 2A: variable decrease in von Willebrand factor Ag and VIII:C with a significant decrease in von Willebrand factor activity and absence of large and intermediate size multimers. Type 2B: variable decrease in von Willebrand factor Ag and VIII:C and a significant decrease in von Willebrand factor activity and absence of large multimers. However, most importantly, this type is hypersensitive to ristocetin-induced platelet aggregation (RIPA). Type M: vWF activity is decreased relative to Ag and multimers are present. Type N: this is characterized variably by a decrease in vWF Ag and activity but is distinguished from the other types by the significant decrease in VIII: C, albeit usually more than 5%. This specific subtype can be confused with hemophilia A.", "contents": "Von Willebrand Disease -- Pathophysiology. A qualitative decrease with specific variations characterizes type II disease: Type 2A: variable decrease in von Willebrand factor Ag and VIII:C with a significant decrease in von Willebrand factor activity and absence of large and intermediate size multimers. Type 2B: variable decrease in von Willebrand factor Ag and VIII:C and a significant decrease in von Willebrand factor activity and absence of large multimers. However, most importantly, this type is hypersensitive to ristocetin-induced platelet aggregation (RIPA). Type M: vWF activity is decreased relative to Ag and multimers are present. Type N: this is characterized variably by a decrease in vWF Ag and activity but is distinguished from the other types by the significant decrease in VIII: C, albeit usually more than 5%. This specific subtype can be confused with hemophilia A."}
{"id": "article-31270_13", "title": "Von Willebrand Disease -- History and Physical", "content": "Low von Willebrand factor\u00a0is quite common in the general population, but not all patients have clinically significant bleeding issues. Therefore, a significant proportion of the patient population goes undiagnosed. Most cases are diagnosed\u00a0formally\u00a0after investigating significant bleeding problems such as recurrent and excessive bruising, prolonged bleeding from minor skin trauma, and prolonged bleeding from mucosal surfaces (epistaxis, dental extractions, menstruation). The physical examination can often be normal. Sometimes evidence of bleeding/bruising (petechiae, hematomas) may be noted.", "contents": "Von Willebrand Disease -- History and Physical. Low von Willebrand factor\u00a0is quite common in the general population, but not all patients have clinically significant bleeding issues. Therefore, a significant proportion of the patient population goes undiagnosed. Most cases are diagnosed\u00a0formally\u00a0after investigating significant bleeding problems such as recurrent and excessive bruising, prolonged bleeding from minor skin trauma, and prolonged bleeding from mucosal surfaces (epistaxis, dental extractions, menstruation). The physical examination can often be normal. Sometimes evidence of bleeding/bruising (petechiae, hematomas) may be noted."}
{"id": "article-31270_14", "title": "Von Willebrand Disease -- History and Physical", "content": "In the case of a qualitative defect, von Willebrand\u00a0disease\u00a0may mimic hemophilia and predominantly present with bleeding into soft tissues, joints, and hematuria rather than mucocutaneous bleeding.\u00a0Sometimes,\u00a0type 2N von Willebrand\u00a0disease\u00a0is misdiagnosed as hemophilia.", "contents": "Von Willebrand Disease -- History and Physical. In the case of a qualitative defect, von Willebrand\u00a0disease\u00a0may mimic hemophilia and predominantly present with bleeding into soft tissues, joints, and hematuria rather than mucocutaneous bleeding.\u00a0Sometimes,\u00a0type 2N von Willebrand\u00a0disease\u00a0is misdiagnosed as hemophilia."}
{"id": "article-31270_15", "title": "Von Willebrand Disease -- Evaluation", "content": "Patients with a clinical history consistent with von Willebrand disease\u00a0are investigated further with the following labs:", "contents": "Von Willebrand Disease -- Evaluation. Patients with a clinical history consistent with von Willebrand disease\u00a0are investigated further with the following labs:"}
{"id": "article-31270_16", "title": "Von Willebrand Disease -- Evaluation", "content": "Complete blood count (CBC): Platelet levels tend to be normal", "contents": "Von Willebrand Disease -- Evaluation. Complete blood count (CBC): Platelet levels tend to be normal"}
{"id": "article-31270_17", "title": "Von Willebrand Disease -- Evaluation", "content": "Coagulation profile: aPTT may be prolonged, as there would be increased factor VIII degradation in von Willebrand disease. PT should be normal.", "contents": "Von Willebrand Disease -- Evaluation. Coagulation profile: aPTT may be prolonged, as there would be increased factor VIII degradation in von Willebrand disease. PT should be normal."}
{"id": "article-31270_18", "title": "Von Willebrand Disease -- Evaluation", "content": "Von Willebrand factor\u00a0antigen: von Willebrand factor\u00a0protein levels are measured. This is a test for a quantitative defect.", "contents": "Von Willebrand Disease -- Evaluation. Von Willebrand factor\u00a0antigen: von Willebrand factor\u00a0protein levels are measured. This is a test for a quantitative defect."}
{"id": "article-31270_19", "title": "Von Willebrand Disease -- Evaluation", "content": "Von Willebrand factor\u00a0activity: This is a qualitative analysis for von Willebrand factor\u00a0physiological function. This is tested through Ristocetin cofactor activity (vWF:RCo) and collagen binding activity (vWF:CB). Normal Ristocetin cofactor activity levels are above 50 IU/dL. Levels below 30 are diagnostic for von Willebrand disease.", "contents": "Von Willebrand Disease -- Evaluation. Von Willebrand factor\u00a0activity: This is a qualitative analysis for von Willebrand factor\u00a0physiological function. This is tested through Ristocetin cofactor activity (vWF:RCo) and collagen binding activity (vWF:CB). Normal Ristocetin cofactor activity levels are above 50 IU/dL. Levels below 30 are diagnostic for von Willebrand disease."}
{"id": "article-31270_20", "title": "Von Willebrand Disease -- Evaluation", "content": "Factor VIII Activity: Decreased von Willebrand factor leads to increased degradation of factor VIII.", "contents": "Von Willebrand Disease -- Evaluation. Factor VIII Activity: Decreased von Willebrand factor leads to increased degradation of factor VIII."}
{"id": "article-31270_21", "title": "Von Willebrand Disease -- Evaluation", "content": "Von Willebrand factor\u00a0activity/antigen ratio: This helps identify cases with a significant qualitative deficit. A low ratio should raise suspicion for type 2 von Willebrand disease; however, absolute normal values have yet to be determined.", "contents": "Von Willebrand Disease -- Evaluation. Von Willebrand factor\u00a0activity/antigen ratio: This helps identify cases with a significant qualitative deficit. A low ratio should raise suspicion for type 2 von Willebrand disease; however, absolute normal values have yet to be determined."}
{"id": "article-31270_22", "title": "Von Willebrand Disease -- Evaluation", "content": "Patients with\u00a0von Willebrand disease\u00a0activity/antigen levels between 30 and 50 should be designated as \u201clow-von Willebrand factor\u201d and be considered for treatment in high bleeding risk scenarios.", "contents": "Von Willebrand Disease -- Evaluation. Patients with\u00a0von Willebrand disease\u00a0activity/antigen levels between 30 and 50 should be designated as \u201clow-von Willebrand factor\u201d and be considered for treatment in high bleeding risk scenarios."}
{"id": "article-31270_23", "title": "Von Willebrand Disease -- Treatment / Management", "content": "Stable patients with type 1, some type 2 (except type 2B), and acquired von Willebrand disease\u00a0patients are given a trial of desmopressin (DDAVP), which is a synthetic analog of vasopressin to check for a response. This is usually performed when patients are not actively bleeding. [7] [8] [9]", "contents": "Von Willebrand Disease -- Treatment / Management. Stable patients with type 1, some type 2 (except type 2B), and acquired von Willebrand disease\u00a0patients are given a trial of desmopressin (DDAVP), which is a synthetic analog of vasopressin to check for a response. This is usually performed when patients are not actively bleeding. [7] [8] [9]"}
{"id": "article-31270_24", "title": "Von Willebrand Disease -- Treatment / Management", "content": "Type 1 usually shows a good response to the DDAVP trial. Type 2A shows a variable and transient response which is often clinically adequate. Type 2M and Type 2N usually show a poor or minimal response. Type 3 von Willebrand disease\u00a0does not respond to Desmopressin as there is a complete lack of von Willebrand factor. A successful trial sees von Willebrand factor\u00a0activity levels of at least 30 IU/dL (ideally 50 IU/dL). Desmopressin causes von Willebrand factor\u00a0release from endothelial cells. DDVAP can be administered subcutaneously, intravenously, and via intranasal spray. It leads to increased von Willebrand factor\u00a0and factor VIII levels, with response persisting for up to 12 hours. It is useful for minor bleeding episodes (including epistaxis and menses) and elective minimally invasive surgical procedures.", "contents": "Von Willebrand Disease -- Treatment / Management. Type 1 usually shows a good response to the DDAVP trial. Type 2A shows a variable and transient response which is often clinically adequate. Type 2M and Type 2N usually show a poor or minimal response. Type 3 von Willebrand disease\u00a0does not respond to Desmopressin as there is a complete lack of von Willebrand factor. A successful trial sees von Willebrand factor\u00a0activity levels of at least 30 IU/dL (ideally 50 IU/dL). Desmopressin causes von Willebrand factor\u00a0release from endothelial cells. DDVAP can be administered subcutaneously, intravenously, and via intranasal spray. It leads to increased von Willebrand factor\u00a0and factor VIII levels, with response persisting for up to 12 hours. It is useful for minor bleeding episodes (including epistaxis and menses) and elective minimally invasive surgical procedures."}
{"id": "article-31270_25", "title": "Von Willebrand Disease -- Treatment / Management", "content": "Von Willebrand factor\u00a0replacement can be considered in patients with type 3 von Willebrand disease or severe variants of type 1 and two that do not demonstrate a sufficient DDAVP response in serious bleeding scenarios. There are many different preparations available, including factor VIII concentrates that also include von Willebrand factor.\u00a0Von Willebrand factor\u00a0replacement therapy often\u00a0is used in serious bleeding scenarios such as trauma or major surgery. Usually, it is administered as a short course. Examples of intermediate-purity vWF concentrates include\u00a0single factor formulations like alphanate and\u00a0others that contain both vWF and FVIII. Patients with von Willebrand disease type III need the products mentioned above for episodes of bleeding or surgery. Conversely, for mild type I and type II A disease (or minor procedures in this category), DDAVP might suffice. However, other scenarios might require von Willebrand and FVIII factors mentioned previously.", "contents": "Von Willebrand Disease -- Treatment / Management. Von Willebrand factor\u00a0replacement can be considered in patients with type 3 von Willebrand disease or severe variants of type 1 and two that do not demonstrate a sufficient DDAVP response in serious bleeding scenarios. There are many different preparations available, including factor VIII concentrates that also include von Willebrand factor.\u00a0Von Willebrand factor\u00a0replacement therapy often\u00a0is used in serious bleeding scenarios such as trauma or major surgery. Usually, it is administered as a short course. Examples of intermediate-purity vWF concentrates include\u00a0single factor formulations like alphanate and\u00a0others that contain both vWF and FVIII. Patients with von Willebrand disease type III need the products mentioned above for episodes of bleeding or surgery. Conversely, for mild type I and type II A disease (or minor procedures in this category), DDAVP might suffice. However, other scenarios might require von Willebrand and FVIII factors mentioned previously."}
{"id": "article-31270_26", "title": "Von Willebrand Disease -- Treatment / Management", "content": "Tranexamic acid can also be used as an anti-fibrinolytic agent. It prevents the breakdown of fibrin clots. It is useful in case of mucosal bleeding. [10]", "contents": "Von Willebrand Disease -- Treatment / Management. Tranexamic acid can also be used as an anti-fibrinolytic agent. It prevents the breakdown of fibrin clots. It is useful in case of mucosal bleeding. [10]"}
{"id": "article-31270_27", "title": "Von Willebrand Disease -- Differential Diagnosis", "content": "Factor X deficiency Factor XI deficiency Hemophilia A Hemophilia B Bernard-Soulier syndrome Platelet function defects Antiplatelet drug ingestion Fibrinolytic defects", "contents": "Von Willebrand Disease -- Differential Diagnosis. Factor X deficiency Factor XI deficiency Hemophilia A Hemophilia B Bernard-Soulier syndrome Platelet function defects Antiplatelet drug ingestion Fibrinolytic defects"}
{"id": "article-31270_28", "title": "Von Willebrand Disease -- Prognosis", "content": "For the majority of patients, vWD is a mild, manageable bleeding disorder. Clinically severe hemorrhage is usually only seen with trauma or invasive procedures.", "contents": "Von Willebrand Disease -- Prognosis. For the majority of patients, vWD is a mild, manageable bleeding disorder. Clinically severe hemorrhage is usually only seen with trauma or invasive procedures."}
{"id": "article-31270_29", "title": "Von Willebrand Disease -- Complications", "content": "Alloantibody formation\u00a0can occur\u00a0in 10\u00a0to 15% of patients with type 3 disease.\u00a0This means that the potential for\u00a0this complication\u00a0requires appropriate\u00a0management\u00a0as these\u00a0patients\u00a0have an increased risk for life-threatening anaphylactic reactions to vWF-FVIII preparations.\u00a0During pregnancy, vWF levels increase in most women with types 1 and 2 vWD; labor and delivery are typically normal. However, patients with type 2B disease may experience hemorrhagic problems. Women with vWD whose vWF does not rise to normal levels during pregnancy\u00a0require\u00a0assessment with a specialist and\u00a0interprofessional team management.", "contents": "Von Willebrand Disease -- Complications. Alloantibody formation\u00a0can occur\u00a0in 10\u00a0to 15% of patients with type 3 disease.\u00a0This means that the potential for\u00a0this complication\u00a0requires appropriate\u00a0management\u00a0as these\u00a0patients\u00a0have an increased risk for life-threatening anaphylactic reactions to vWF-FVIII preparations.\u00a0During pregnancy, vWF levels increase in most women with types 1 and 2 vWD; labor and delivery are typically normal. However, patients with type 2B disease may experience hemorrhagic problems. Women with vWD whose vWF does not rise to normal levels during pregnancy\u00a0require\u00a0assessment with a specialist and\u00a0interprofessional team management."}
{"id": "article-31270_30", "title": "Von Willebrand Disease -- Complications", "content": "Some of the less common but more serious include\u00a0GI bleeding, hematomas, and hemarthrosis, potentially leading\u00a0to progressive joint damage and degeneration. In these cases, VWD\u00a0limit the range of motion of an affected joint.", "contents": "Von Willebrand Disease -- Complications. Some of the less common but more serious include\u00a0GI bleeding, hematomas, and hemarthrosis, potentially leading\u00a0to progressive joint damage and degeneration. In these cases, VWD\u00a0limit the range of motion of an affected joint."}
{"id": "article-31270_31", "title": "Von Willebrand Disease -- Deterrence and Patient Education", "content": "Patient education requires counsel\u00a0about the bleeding risk; this should include\u00a0advice regarding drugs\u00a0to avoid, including antiplatelet drugs and non-steroidal anti-inflammatory drugs\u00a0(NSAIDs). They should also understand that certain high-risk activities (e.g., contact sports) will be off-limits for them. While patients need to be cognizant of their risk, they should also\u00a0receive reassurance that minor bleeding issues, such as nosebleeds or bruising, may not\u00a0necessitate any specific treatment.", "contents": "Von Willebrand Disease -- Deterrence and Patient Education. Patient education requires counsel\u00a0about the bleeding risk; this should include\u00a0advice regarding drugs\u00a0to avoid, including antiplatelet drugs and non-steroidal anti-inflammatory drugs\u00a0(NSAIDs). They should also understand that certain high-risk activities (e.g., contact sports) will be off-limits for them. While patients need to be cognizant of their risk, they should also\u00a0receive reassurance that minor bleeding issues, such as nosebleeds or bruising, may not\u00a0necessitate any specific treatment."}
{"id": "article-31270_32", "title": "Von Willebrand Disease -- Pearls and Other Issues", "content": "Von Willebrand disease\u00a0in females is often a more clinically severe disease due to menorrhagia.", "contents": "Von Willebrand Disease -- Pearls and Other Issues. Von Willebrand disease\u00a0in females is often a more clinically severe disease due to menorrhagia."}
{"id": "article-31270_33", "title": "Von Willebrand Disease -- Pearls and Other Issues", "content": "Von Willebrand factor\u00a0levels vary with physiological stress. Some patients may occasionally be noted to have normal von Willebrand factor\u00a0levels. A clinically suspect patient should be retested in a few weeks if initial von Willebrand factor\u00a0levels are normal.", "contents": "Von Willebrand Disease -- Pearls and Other Issues. Von Willebrand factor\u00a0levels vary with physiological stress. Some patients may occasionally be noted to have normal von Willebrand factor\u00a0levels. A clinically suspect patient should be retested in a few weeks if initial von Willebrand factor\u00a0levels are normal."}
{"id": "article-31270_34", "title": "Von Willebrand Disease -- Pearls and Other Issues", "content": "Von Willebrand factor\u00a0levels are adjusted according to ABO blood grouping.", "contents": "Von Willebrand Disease -- Pearls and Other Issues. Von Willebrand factor\u00a0levels are adjusted according to ABO blood grouping."}
{"id": "article-31270_35", "title": "Von Willebrand Disease -- Pearls and Other Issues", "content": "Sodium levels require measurement\u00a0in patients taking DDAVP as multiple doses along with free fluid intake can cause severe Hyponatremia. Similarly, NSAIDs should be used with caution as they can worsen hyponatremia.", "contents": "Von Willebrand Disease -- Pearls and Other Issues. Sodium levels require measurement\u00a0in patients taking DDAVP as multiple doses along with free fluid intake can cause severe Hyponatremia. Similarly, NSAIDs should be used with caution as they can worsen hyponatremia."}
{"id": "article-31270_36", "title": "Von Willebrand Disease -- Pearls and Other Issues", "content": "Prolonged DDAVP use can lead to tachyphylaxis.", "contents": "Von Willebrand Disease -- Pearls and Other Issues. Prolonged DDAVP use can lead to tachyphylaxis."}
{"id": "article-31270_37", "title": "Von Willebrand Disease -- Pearls and Other Issues", "content": "DDAVP and anti-fibrinolytic agents carry a\u00a0thrombosis risk.\u00a0Von Willebrand factor\u00a0replacement therapy is preferable in patients with cardiovascular\u00a0or cerebrovascular disease.", "contents": "Von Willebrand Disease -- Pearls and Other Issues. DDAVP and anti-fibrinolytic agents carry a\u00a0thrombosis risk.\u00a0Von Willebrand factor\u00a0replacement therapy is preferable in patients with cardiovascular\u00a0or cerebrovascular disease."}
{"id": "article-31270_38", "title": "Von Willebrand Disease -- Pearls and Other Issues", "content": "Tranexamic acid is not recommended in gross haematuria. Clots can form and cause ureteric or urethral obstruction.", "contents": "Von Willebrand Disease -- Pearls and Other Issues. Tranexamic acid is not recommended in gross haematuria. Clots can form and cause ureteric or urethral obstruction."}
{"id": "article-31270_39", "title": "Von Willebrand Disease -- Pearls and Other Issues", "content": "Though generally avoided due to viral transmission risk, cryoprecipitate and fresh\u00a0frozen plasma (FFP) can be used in life-threatening scenarios.", "contents": "Von Willebrand Disease -- Pearls and Other Issues. Though generally avoided due to viral transmission risk, cryoprecipitate and fresh\u00a0frozen plasma (FFP) can be used in life-threatening scenarios."}
{"id": "article-31270_40", "title": "Von Willebrand Disease -- Pearls and Other Issues", "content": "DDAVP dosing is 0.3 micrograms/Kg administered over 20 to 30 minutes.", "contents": "Von Willebrand Disease -- Pearls and Other Issues. DDAVP dosing is 0.3 micrograms/Kg administered over 20 to 30 minutes."}
{"id": "article-31270_41", "title": "Von Willebrand Disease -- Enhancing Healthcare Team Outcomes", "content": "The management of Von Willebrand's disease\u00a0requires an interprofessional healthcare team. This includes specialists, clinicians at all levels (MDs, DOs, NPs PAs), pharmacists, and nursing staff. While the hematologist usually manages acute bleeding episodes, the follow-up is usually by the primary caregiver or nurse practitioner. When all these different disciplines collaborate and coordinate their activities with open communication, the patient will benefit, enhancing the odds for improved outcomes. [Level 5]", "contents": "Von Willebrand Disease -- Enhancing Healthcare Team Outcomes. The management of Von Willebrand's disease\u00a0requires an interprofessional healthcare team. This includes specialists, clinicians at all levels (MDs, DOs, NPs PAs), pharmacists, and nursing staff. While the hematologist usually manages acute bleeding episodes, the follow-up is usually by the primary caregiver or nurse practitioner. When all these different disciplines collaborate and coordinate their activities with open communication, the patient will benefit, enhancing the odds for improved outcomes. [Level 5]"}
{"id": "article-31270_42", "title": "Von Willebrand Disease -- Enhancing Healthcare Team Outcomes", "content": "The key to the prevention of bleeding is patient education. Patients should\u00a0understand\u00a0to avoid high-risk sporting activities or contact sports. More importantly, they should be told about the signs and symptoms of bleeding and when to seek medical help.", "contents": "Von Willebrand Disease -- Enhancing Healthcare Team Outcomes. The key to the prevention of bleeding is patient education. Patients should\u00a0understand\u00a0to avoid high-risk sporting activities or contact sports. More importantly, they should be told about the signs and symptoms of bleeding and when to seek medical help."}
{"id": "article-31270_43", "title": "Von Willebrand Disease -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Von Willebrand Disease -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}